Tradestie Institutional Equity Comparison Engine

ZBIO vs TWST โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TWST Overall Edge

TWST Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Twist Bioscience Corporation Common Stock (TWST) driven by superior Growth & Margin, Momentum & Technical while ZBIO counters with relative strength in Options & Structure. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus TWST at N/M Forward P/E and -28.8% operating margin (+27.9% YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against TWST sits in CONSOLIDATION (19th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ZBIO N/M vs TWST N/M Fwd P/E
Growth & Margin Winner TWST
Op Margin -2747.5% vs -28.8% ยท YoY -100.0% vs +27.9%
Momentum & Technical Winner TWST
1Y -21.7% vs +251.3% ยท 52W Pos 46% vs 42%
Options & Structure Winner ZBIO
CONSOLIDATION (13th %ile IV) vs CONSOLIDATION (19th %ile IV)
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
TWST NASDAQ
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.04
-5.88% 1D
Market Cap $7.4B
1M Return -20.87%
1Y Return +251.3%
Forward P/E N/M
Unified AI Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZBIO -21.68% TWST +251.3% Spread: +272.98 pp (TWST Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ZBIO Revenue TWST Revenue ZBIO Op. Margin TWST Op. Margin Margin Edge
FY2018 N/A $30M N/A -277.5% TWST
FY2019 N/A $50M N/A -200.1% TWST
FY2020 N/A $90M N/A -155.5% TWST
FY2021 N/A $130M N/A -115.4% TWST
FY2022 N/A $200M N/A -115.3% TWST
FY2023 $50M $250M -74.3% -88.6% ZBIO
FY2024 $10M $310M -3277.8% -70.6% TWST
FY2025 $10M $380M -3830.6% -36.2% TWST

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZBIO (3) vs TWST (5)
Institutional Metric ZBIO TWST Criterion Row Winner
Market Capitalization Scale $1.9B $7.4B Larger Scale TWST
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% +27.9% Higher Growth TWST
Operating Margin (TTM) Profitability -2747.5% -28.8% Higher Margin TWST
Net Profit Margin Profitability 0.0% -28.3% Higher Margin ZBIO
Return on Equity (ROE) Capital Efficiency -265.1% -19.1% Higher ROE TWST
52-Week Range Position Momentum 46% ($14โ€“$45) 42% ($23โ€“$220) Stronger Trend ZBIO
Beta / 30D Volatility Risk Regime 1.16ฮฒ ยท 59% Vol 3.13ฮฒ ยท 126% Vol Lower Realized Risk ZBIO
Unified Institutional Score Composite Signal 49.4 / 100 (HOLD) 51.7 / 100 (HOLD) Higher Composite TWST

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZBIO vs TWST Buy Guide
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TWST CONSOLIDATION
69d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 19th %ile
IV Regime Compressed (<25th %ile)
Live TWST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZBIO nor TWST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.